Millennium Management
NGNE icon

Millennium Management’s Neurogene NGNE Stock Holding History

Millennium Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.13M Buy
204,809
+133,488
+187% +$2.59M ﹤0.01% 3164
2025
Q4 		$1.47M Sell
71,321
-176,543
-71% -$4.39M ﹤0.01% 4202
2025
Q3 		$4.3M Sell
247,864
-59,941
-19% -$1.2M ﹤0.01% 3295
2025
Q2 		$4.6M Buy
307,805
+149,868
+95% +$2.35M ﹤0.01% 3080
2025
Q1 		$1.85M Buy
+157,937
New +$2.74M ﹤0.01% 3854
2024
Q4 		– Sell
-43,700
Closed -$1.83M – 6284
2024
Q3 		$1.83M Buy
43,700
+18,964
+77% +$735K ﹤0.01% 3773
2024
Q2 		$900K Sell
24,736
-58,684
-70% -$2.07M ﹤0.01% 4171
2024
Q1 		$4.25M Buy
+83,420
New +$2.79M ﹤0.01% 3032
2023
Q4 		– Sell
-9,439
Closed -$149K – 6371
2023
Q3 		$149K Sell
9,439
-21,044
-69% -$311K ﹤0.01% 5223
2023
Q2 		$506K Sell
30,483
-8,374
-22% -$137K ﹤0.01% 4534
2023
Q1 		$544K Sell
38,857
-40,506
-51% -$475K ﹤0.01% 4553
2022
Q4 		$808K Sell
79,363
-5,406
-6% -$55.8K ﹤0.01% 4364
2022
Q3 		$1.08M Sell
84,769
-21,038
-20% -$429K ﹤0.01% 4267
2022
Q2 		$2.18M Buy
105,807
+44,022
+71% +$1.07M ﹤0.01% 3619
2022
Q1 		$2.32M Buy
61,785
+20,322
+49% +$1.19M ﹤0.01% 3737
2021
Q4 		$4M Buy
41,463
+27,437
+196% +$3.34M ﹤0.01% 3127
2021
Q3 		$2.03M Buy
14,026
+6,127
+78% +$938K ﹤0.01% 3900
2021
Q2 		$1.46M Buy
7,899
+582
+8% +$129K ﹤0.01% 4295
2021
Q1 		$1.8M Buy
7,317
+172
+2% +$44K ﹤0.01% 3632
2020
Q4 		$2.02M Buy
7,145
+3,817
+115% +$933K ﹤0.01% 3227
2020
Q3 		$799 Sell
3,328
-6,756
-67% -$1.64M ﹤0.01% 3294
2020
Q2 		$3.35M Sell
10,084
-27,563
-73% -$7.18M ﹤0.01% 2123
2020
Q1 		$8.57M Buy
37,647
+35,265
+1,480% +$7.26M 0.02% 961
2019
Q4 		$587K Sell
2,382
-18,078
-88% -$1.8M ﹤0.01% 3290
2019
Q3 		$1.17M Buy
+20,460
New +$1.25M ﹤0.01% 2758
2018
Q4 		– Sell
-4,553
Closed -$267K – 4037
2018
Q3 		$267K Sell
4,553
-1,400
-24% -$82.6K ﹤0.01% 3531
2018
Q2 		$315K Sell
5,953
-918
-13% -$239K ﹤0.01% 3369
2018
Q1 		$1.94M Sell
6,871
-36
-0.5% -$9.94K ﹤0.01% 2342
2017
Q4 		$1.62M Buy
6,907
+5,842
+549% +$1.37M ﹤0.01% 2409
2017
Q3 		$302K Buy
1,065
+183
+21% +$52.5K ﹤0.01% 3059
2017
Q2 		$248K Buy
+882
New +$252K ﹤0.01% 3107
2017
Q1 		– Sell
-1,815
Closed -$599K – 3732
2016
Q4 		$599K Buy
+1,815
New +$488K ﹤0.01% 2585
2016
Q3 		– Sell
-2,752
Closed -$364K – 3495
2016
Q2 		$364K Buy
2,752
+2,048
+291% +$326K ﹤0.01% 2643
2016
Q1 		$124K Sell
704
-856
-55% -$166K ﹤0.01% 3053
2015
Q4 		$389K Sell
1,560
-1,241
-44% -$327K ﹤0.01% 2783
2015
Q3 		$788K Buy
+2,801
New +$645K ﹤0.01% 2414

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Millennium Management's NGNE Position: Q1 2026 in Review

Millennium Management increased its Neurogene (NGNE) stake by 187% in Q1 2026, buying an estimated $2.59M and bringing the position to 204,809 shares worth $4.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3164.

Millennium Management first reported a position in NGNE in Q3 2015 and has held it in 36 quarters since. The position peaked at $8.57M in Q1 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Millennium Management held 204,809 shares of Neurogene worth $4.13M as of Q1 2026.
  • Millennium Management bought 133,488 Neurogene shares in Q1 2026, an estimated $2.59M.
  • Neurogene made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3164 holding.
  • Millennium Management first reported a position in Neurogene in Q3 2015 and has held it in 36 quarters since.
  • Millennium Management's Neurogene position peaked at $8.57M in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.